27 completed, 14 recruiting, 13 active not recruiting, 6 unknown. 69 Phase 1, 42 Phase 2.
Follow Retinitis Pigmentosa: new trials by email Literature Review of Retinitis Pigmentosa trials Research Report on Retinitis Pigmentosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa ULREA-PVS-NP - Retinitis Pigmentosa (RP) | Phase 1 | Recruiting | Kyushu University | 21 | 2026-10-01 | 2026-10-07 |
| Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa UGX202 Injection - Retinitis Pigmentosa (RP) | Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 12 | 2026-09-28 | 2026-10-02 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients 9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa | Phase 1 / Phase 2 | Enrolling by invitation | Sheba Medical Center | 41 | 2026-07-26 | 2026-07-27 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 12 | 2026-04-16 | 2026-04-17 |
| A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Octant, Inc. | 18 | 2026-03-10 | 2026-09-24 |
| The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa Alga Dunaliella Bardawil powder, Placebo:Starch - Retinitis Pigmentosa | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 30 | 2026-03-01 | 2025-10-06 |
| Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose) - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Phase 1 / Phase 2 | Recruiting | SparingVision | 27 | 2025-10-08 | 2026-09-08 |
| Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation ZVS203e - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Chigenovo Co., Ltd | 18 | 2025-08-04 | 2026-06-17 |
| Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases Intravitreal Adalimumab - Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP) | Phase 1 / Phase 2 | Active not recruiting | Centro de Pesquisa Rubens Siqueira | 30 | 2025-07-10 | 2026-10-27 |
| The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration Oral disulfiram - Alcohol Use Disorder, Retinal Dystrophies | Phase 1 | Recruiting | University of Rochester | 15 | 2025-05-19 | 2026-09-16 |
| An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa IGT001 - Retinitis Pigmentosa | Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 21 | 2025-04-20 | 2025-04-27 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies ACE Retino - Retinitis Pigmentosa (RP), Age Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Ace Cells Lab Limited | 100 | 2024-11-12 | 2025-04-25 |
| BF844 Safety and Pharmacokinetic Study in Healthy Volunteers BF844 - Usher Syndrome Type 3 | Phase 1 | Unknown | EyeXCel Pty. Ltd. | 76 | 2024-09-09 | 2024-09-19 |
| Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) RTx-015 - Retinitis Pigmentosa, Choroideremia | Phase 1 | Active not recruiting | Ray Therapeutics, Inc. | 10 | 2024-08-27 | 2026-02-20 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa GMP compliant-BM-MSC derived sEVs - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Mahidol University | 15 | 2024-05-23 | 2025-05-15 |
| Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene VG901 - Retinitis Pigmentosa | Phase 1 | Recruiting | VeonGen Therapeutics GmbH | 6 | 2023-09-01 | 2025-03-28 |
Showing 20 of 69. Sign in to see all of them.
Eye Diseases (10) · Retinal Degeneration (10) · Retinal Diseases (9) · Usher Syndromes (6) · Cone-Rod Dystrophies (5) · Retinal Dystrophies (5) · Eye Diseases, Hereditary (4) · Macular Degeneration (4) · Choroideremia (3) · Diabetic Retinopathy (3) · Leber Congenital Amaurosis (3) · Vision Disorders (3) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (2) · Stargardt Disease (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (69) · Genetic Diseases, Inborn (69) · Eye Diseases, Hereditary (64) · Retinal Dystrophies (64) · Retinal Diseases (60) · Eye Diseases (59) · Retinal Degeneration (59) · Nervous System Diseases (10) · Neurologic Manifestations (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Sensation Disorders (8) · Abnormalities, Multiple (6) · Blindness (6) · Congenital Abnormalities (6)
retinol acetate (3) · salicylhydroxamic acid (2) · Acetylcysteine (1) · Brimonidine Tartrate (1) · Culture Media, Conditioned (1) · Disulfiram (1) · Genetic Therapy (1) · Hydroxychloroquine (1) · Intravitreal Injections (1) · KPNA1 protein, human (1) · Lutein (1) · Minocycline (1) · Ophthalmic Solutions (1) · Solutions (1) · Stem Cell Transplantation (1)
Johns Hopkins University (3) · National Eye Institute (NEI) (3) · QLT Inc. (3) · Sheba Medical Center (3) · Mahidol University (2) · ProQR Therapeutics (2) · SparingVision (2) · University of California, Davis (2) · AAVantgarde Bio Srl (1) · AbbVie (1) · Abliva AB (1) · Ace Cells Lab Limited (1) · Acibadem University (1) · Allergan (1) · Bionic Sight LLC (1)
United States (32) · France (8) · United Kingdom (7) · Germany (5) · Canada (4) · Australia (3) · Brazil (3) · China (3) · Israel (3) · India (2) · Ireland (2) · Italy (2) · Netherlands (2) · Spain (2) · Thailand (2)
Sushanta Mallick (3) · Rubens C Siqueira, MD,PhD (2) · Andrew J Lotery, MD (1) · Andrew R Webster, MD (1) · Baruch Kuppermann, MD (1) · Bayu W Putera, S.Si, M.Kes (1) · Benedict Tan, MBBS, FRACP (1) · Catherine A Cukras, M.D. (1)
PMID 32573764, PMID 16759390, PMID 16896916, PMID 20169166, PMID 22828504, PMID 23049090, PMID 24439297, PMID 24705452, PMID 25030840, PMID 25491299, PMID 25744334, PMID 26427420, PMID 26448901, PMID 26656277, PMID 26857842, PMID 27403996, PMID 27820636, PMID 30194931, PMID 30218651, PMID 30646425, PMID 31215818, PMID 31805012, PMID 33422139, PMID 36882562, PMID 37418643, PMID 37743503, PMID 39256350, PMID 39878701, PMID 40547876, PMID 40759732, PMID 40927136, PMID 41769936, PMID 41981307, PMID 42193355, PMID 42842903
2016 (2), 2009 (1), 2017 (1), 2018 (1), 2025 (1)